CEO Gary Phillips speaks with JustStocks following the news we have completed full recruitment of our Phase 2 trial evaluating SNT-5055 in combination with ruxolitinib treating the bone marrow cancer myelofibrosis.
Click to watch the interview here
Share
Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.
